Gravity Analytica

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

RSLS 11.12.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-14

Name of Upcoming Event:Conference Call

Full Press Release SEC Filings Our RSLS Tweets

About Gravity Analytica

Recent Filings

PDF Version

Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024

IRVINE, Calif.,Nov. 12, 2024(GLOBE NEWSWIRE) --ReShape Lifesciences Inc.(Nasdaq: RSLS),the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter endedSeptember 30, 2024, including a corporate update onThursday, November 14, 2024, after market.

Management will host a conference call onThursday, November 14at4:30 pm ET, and will be joined byKrishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the “Events and Presentations” section of ReShape’s website at:https://ir.reshapelifesciences.com/events-and-presentations.

To participate in the conference call please register with the followingRegistration Link, and dial-in details will be provided. Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.

An archived replay will also be available on the “Events and Presentations” section of ReShape’s website at:https://ir.reshapelifesciences.com/events-and-presentations.

About ReShape Lifesciences®

ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim NeuromodulationTM (DBSNTM) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visitwww.reshapelifesciences.com.

CONTACTS:

ReShape Lifesciences Contact:Paul F. HickeyPresident and Chief Executive Officer949-276-7223ir@ReShapeLifesci.com

Investor Relations Contact:Rx Communications GroupMichael Miller(917)-633-6086mmiller@rxir.com

Source: ReShape Lifesciences Inc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com